Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | REPL |
---|---|---|
09:32 ET | 6030 | 10.99 |
09:34 ET | 1500 | 10.98 |
09:36 ET | 1938 | 10.96 |
09:38 ET | 300 | 10.96 |
09:39 ET | 1000 | 10.875 |
09:41 ET | 1599 | 10.86 |
09:43 ET | 505 | 10.88 |
09:45 ET | 4562 | 10.825 |
09:48 ET | 5509 | 10.775 |
09:50 ET | 1110 | 10.795 |
09:52 ET | 400 | 10.77 |
09:54 ET | 800 | 10.77 |
09:56 ET | 5893 | 10.735 |
09:57 ET | 4000 | 10.77 |
09:59 ET | 2500 | 10.79 |
10:01 ET | 5383 | 10.86 |
10:03 ET | 500 | 10.855 |
10:06 ET | 600 | 10.845 |
10:08 ET | 4998 | 10.775 |
10:10 ET | 3131 | 10.75 |
10:12 ET | 3434 | 10.71 |
10:14 ET | 4952 | 10.78 |
10:15 ET | 1240 | 10.795 |
10:17 ET | 1028 | 10.7933 |
10:19 ET | 12902 | 10.79 |
10:21 ET | 300 | 10.79 |
10:24 ET | 2900 | 10.81 |
10:26 ET | 800 | 10.825 |
10:28 ET | 4895 | 10.785 |
10:30 ET | 400 | 10.78 |
10:32 ET | 2300 | 10.78 |
10:33 ET | 1245 | 10.795 |
10:35 ET | 1628 | 10.825 |
10:37 ET | 1006 | 10.835 |
10:39 ET | 300 | 10.85 |
10:42 ET | 13237 | 10.915 |
10:44 ET | 1323 | 10.94 |
10:46 ET | 1296 | 10.975 |
10:48 ET | 3362 | 10.99 |
10:50 ET | 5130 | 10.955 |
10:51 ET | 2343 | 10.925 |
10:53 ET | 3387 | 10.96 |
10:55 ET | 1890 | 10.99 |
10:57 ET | 1544 | 10.99 |
11:00 ET | 1450 | 11.015 |
11:02 ET | 500 | 11.005 |
11:04 ET | 1450 | 10.995 |
11:06 ET | 2841 | 10.965 |
11:08 ET | 6440 | 10.97 |
11:09 ET | 2030 | 10.97 |
11:11 ET | 402 | 10.99 |
11:13 ET | 200 | 11.025 |
11:15 ET | 942 | 11.05 |
11:18 ET | 3174 | 11.03 |
11:20 ET | 4552 | 11 |
11:22 ET | 2171 | 11.01 |
11:24 ET | 650 | 11.04 |
11:26 ET | 1746 | 11.03 |
11:27 ET | 4811 | 11.05 |
11:29 ET | 7521 | 11.03 |
11:31 ET | 2642 | 11.03 |
11:33 ET | 100 | 11.04 |
11:36 ET | 2487 | 11.06 |
11:38 ET | 5648 | 11.04 |
11:40 ET | 100 | 11.03 |
11:42 ET | 1861 | 11.02 |
11:44 ET | 3188 | 11.13 |
11:45 ET | 1882 | 11.195 |
11:47 ET | 700 | 11.21 |
11:49 ET | 815 | 11.21 |
11:51 ET | 7728 | 11.16 |
11:54 ET | 1861 | 11.2 |
11:56 ET | 3443 | 11.225 |
11:58 ET | 1300 | 11.2 |
12:00 ET | 7745 | 11.25 |
12:02 ET | 5461 | 11.34 |
12:03 ET | 3133 | 11.27 |
12:05 ET | 1600 | 11.28 |
12:07 ET | 3753 | 11.26 |
12:09 ET | 1315 | 11.225 |
12:12 ET | 1163 | 11.21 |
12:14 ET | 1500 | 11.21 |
12:16 ET | 4094 | 11.25 |
12:18 ET | 300 | 11.25 |
12:20 ET | 886 | 11.25 |
12:21 ET | 5011 | 11.25 |
12:23 ET | 1800 | 11.275 |
12:25 ET | 3284 | 11.28 |
12:27 ET | 2316 | 11.28 |
12:30 ET | 1307 | 11.28 |
12:32 ET | 3877 | 11.22 |
12:34 ET | 2129 | 11.17 |
12:36 ET | 4991 | 11.2 |
12:38 ET | 300 | 11.23 |
12:39 ET | 1000 | 11.18 |
12:41 ET | 1735 | 11.16 |
12:43 ET | 200 | 11.16 |
12:45 ET | 800 | 11.16 |
12:48 ET | 1200 | 11.15 |
12:50 ET | 2617 | 11.17 |
12:52 ET | 600 | 11.19 |
12:54 ET | 1723 | 11.22 |
12:56 ET | 1492 | 11.29 |
12:57 ET | 700 | 11.28 |
12:59 ET | 2241 | 11.31 |
01:01 ET | 100 | 11.31 |
01:03 ET | 963 | 11.33 |
01:06 ET | 2764 | 11.35 |
01:08 ET | 3128 | 11.32 |
01:10 ET | 200 | 11.33 |
01:12 ET | 1524 | 11.33 |
01:14 ET | 2340 | 11.33 |
01:15 ET | 4297 | 11.3 |
01:17 ET | 6342 | 11.23 |
01:19 ET | 2213 | 11.25 |
01:21 ET | 200 | 11.27 |
01:24 ET | 817 | 11.27 |
01:26 ET | 1100 | 11.26 |
01:28 ET | 4960 | 11.33 |
01:30 ET | 4622 | 11.35 |
01:32 ET | 3572 | 11.41 |
01:33 ET | 1154 | 11.43 |
01:35 ET | 1735 | 11.47 |
01:37 ET | 4950 | 11.47 |
01:39 ET | 1035 | 11.4892 |
01:42 ET | 7843 | 11.56 |
01:44 ET | 778 | 11.58 |
01:46 ET | 5037 | 11.625 |
01:48 ET | 11716 | 11.62 |
01:50 ET | 1987 | 11.68 |
01:51 ET | 1369 | 11.68 |
01:53 ET | 900 | 11.6659 |
01:55 ET | 3923 | 11.65 |
01:57 ET | 902 | 11.69 |
02:00 ET | 927 | 11.71 |
02:02 ET | 712 | 11.71 |
02:04 ET | 3003 | 11.74 |
02:06 ET | 1816 | 11.61 |
02:08 ET | 1933 | 11.62 |
02:09 ET | 300 | 11.59 |
02:11 ET | 1624 | 11.67 |
02:13 ET | 1664 | 11.7 |
02:15 ET | 665 | 11.71 |
02:18 ET | 6285 | 11.6999 |
02:20 ET | 1900 | 11.65 |
02:22 ET | 1650 | 11.68 |
02:24 ET | 1250 | 11.7 |
02:26 ET | 2801 | 11.72 |
02:27 ET | 1180 | 11.765 |
02:29 ET | 1300 | 11.77 |
02:31 ET | 5663 | 11.75 |
02:33 ET | 2570 | 11.7 |
02:36 ET | 5567 | 11.735 |
02:38 ET | 2921 | 11.72 |
02:40 ET | 5302 | 11.69 |
02:42 ET | 1109 | 11.73 |
02:44 ET | 1600 | 11.68 |
02:45 ET | 1250 | 11.71 |
02:47 ET | 2150 | 11.75 |
02:49 ET | 6372 | 11.73 |
02:51 ET | 1586 | 11.735 |
02:54 ET | 3741 | 11.71 |
02:56 ET | 2434 | 11.7 |
02:58 ET | 4517 | 11.71 |
03:00 ET | 1837 | 11.745 |
03:02 ET | 2324 | 11.74 |
03:03 ET | 2750 | 11.77 |
03:05 ET | 12204 | 11.75 |
03:07 ET | 1710 | 11.77 |
03:09 ET | 2500 | 11.79 |
03:12 ET | 3554 | 11.86 |
03:14 ET | 5034 | 11.78 |
03:16 ET | 3304 | 11.73 |
03:18 ET | 1489 | 11.77 |
03:20 ET | 900 | 11.76 |
03:23 ET | 2566 | 11.76 |
03:25 ET | 1511 | 11.79 |
03:27 ET | 2863 | 11.75 |
03:30 ET | 4467 | 11.79 |
03:32 ET | 4585 | 11.75 |
03:34 ET | 2858 | 11.725 |
03:36 ET | 4680 | 11.72 |
03:38 ET | 3204 | 11.68 |
03:39 ET | 2290 | 11.7 |
03:41 ET | 6182 | 11.69 |
03:43 ET | 2428 | 11.695 |
03:45 ET | 7466 | 11.7 |
03:48 ET | 9413 | 11.73 |
03:50 ET | 7147 | 11.83 |
03:52 ET | 14896 | 11.745 |
03:54 ET | 6605 | 11.745 |
03:56 ET | 57001 | 11.8083 |
03:57 ET | 27937 | 11.87 |
03:59 ET | 150637 | 11.9 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Replimune Group Inc | 813.0M | -3.6x | --- |
Arrivent Biopharma Inc | 799.0M | -9.7x | --- |
Dianthus Therapeutics Inc | 818.4M | -5.0x | --- |
CARGO Therapeutics Inc | 838.7M | -5.3x | --- |
89Bio Inc | 779.5M | -3.7x | --- |
Nuvation Bio Inc | 770.0M | -1.1x | --- |
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $813.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 68.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.19 |
EPS | $-3.27 |
Book Value | $6.10 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.